BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-530@pharmaconomics
DTSTAMP:20260707T041049Z
DTSTART;VALUE=DATE:20260427
DTEND;VALUE=DATE:20260428
SUMMARY:CRMD Phase 3 — Rezafungin
DESCRIPTION:Phase 3 trial results for Rezafungin in invasive fungal diseases are due Apr 27\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1410098/000121390026047748/ea028764001ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/530
URL:https://www.pharmaconomics.com/e/530
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:CRMD catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR